AR126457A1 - Inhibidores peptídicos bicíclicos del receptor de interleuquina-23 - Google Patents

Inhibidores peptídicos bicíclicos del receptor de interleuquina-23

Info

Publication number
AR126457A1
AR126457A1 ARP220101855A ARP220101855A AR126457A1 AR 126457 A1 AR126457 A1 AR 126457A1 AR P220101855 A ARP220101855 A AR P220101855A AR P220101855 A ARP220101855 A AR P220101855A AR 126457 A1 AR126457 A1 AR 126457A1
Authority
AR
Argentina
Prior art keywords
receptor
peptide inhibitors
interleukine
bicyclic peptide
interleukin
Prior art date
Application number
ARP220101855A
Other languages
English (en)
Inventor
Chengzao Sun
Sandeep Somani
Stephanie A Barros
Raymond J Patch
Santhosh Francis Neelamkavil
Jing Zhang
Charles Hendrick
Elisabetta Bianchi
Roberto Constante
Raffaele Ingenito
Danila Branca
Ashok Bhandari
Brian Frederick
Tran Trung Tran
Jie Zhang
Original Assignee
Janssen Biotech Inc
Protagonist Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc, Protagonist Therapeutics Inc filed Critical Janssen Biotech Inc
Publication of AR126457A1 publication Critical patent/AR126457A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Epidemiology (AREA)

Abstract

La presente invención se refiere a nuevos inhibidores peptídicos bicíclicos del receptor de la interleucina-23 (IL-23R) o sales farmacéuticamente aceptables del mismo, composiciones farmacéuticas correspondientes, métodos y/o usos para el tratamiento de la inflamación autoinmune y enfermedades y trastornos relacionados.
ARP220101855A 2021-07-14 2022-07-14 Inhibidores peptídicos bicíclicos del receptor de interleuquina-23 AR126457A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163221854P 2021-07-14 2021-07-14

Publications (1)

Publication Number Publication Date
AR126457A1 true AR126457A1 (es) 2023-10-11

Family

ID=84920518

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP220101855A AR126457A1 (es) 2021-07-14 2022-07-14 Inhibidores peptídicos bicíclicos del receptor de interleuquina-23

Country Status (8)

Country Link
EP (1) EP4370532A2 (es)
KR (1) KR20240034223A (es)
CN (1) CN117980320A (es)
AR (1) AR126457A1 (es)
AU (1) AU2022310347A1 (es)
CA (1) CA3226492A1 (es)
TW (1) TW202321275A (es)
WO (1) WO2023288017A2 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4091624A1 (en) 2013-03-15 2022-11-23 Protagonist Therapeutics, Inc. Hepcidin analogues and uses thereof
DK3143037T3 (da) 2014-05-16 2021-09-20 Protagonist Therapeutics Inc Alpha4beta7-integrin-thioether-peptidantagonister
RU2736637C9 (ru) 2014-07-17 2021-02-08 Протагонист Терепьютикс, Инк. Пептидные ингибиторы рецептора интерлейкина-23 для перорального приема и их применение для лечения воспалительных заболеваний кишечника
WO2019157268A1 (en) 2018-02-08 2019-08-15 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
CA3202226A1 (en) 2020-11-20 2022-05-27 Janssen Pharmaceutica Nv Compositions of peptide inhibitors of interleukin-23 receptor

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016054445A1 (en) * 2014-10-01 2016-04-07 Protagonist Therapeutics, Inc. Novel cyclic monomer and dimer peptides having integrin antagonist activity
EP3341011A4 (en) * 2015-07-15 2019-02-20 Protagonist Therapeutics Inc. PEPTIDINHIBITORS OF THE INTERLEUKIN 23 RECEPTOR AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY DISEASES
JP7100034B2 (ja) * 2016-12-06 2022-07-12 シュティヒティング・ヴォール・デ・テクニシェ・ヴェテンシャッペン 多環式ペプチド及びそれらの調製方法
US20200291096A1 (en) * 2017-08-14 2020-09-17 Bicyclerd Limited Bicyclic peptide ligand sting conjugates and uses thereof
BR112020010941A2 (pt) * 2017-12-15 2020-11-17 Janssen Biotech, Inc. dinucleotídeos cíclicos como agonistas de sting

Also Published As

Publication number Publication date
TW202321275A (zh) 2023-06-01
CA3226492A1 (en) 2023-01-19
AU2022310347A1 (en) 2024-02-29
WO2023288017A2 (en) 2023-01-19
KR20240034223A (ko) 2024-03-13
EP4370532A2 (en) 2024-05-22
CN117980320A (zh) 2024-05-03
WO2023288017A3 (en) 2023-03-09

Similar Documents

Publication Publication Date Title
AR126457A1 (es) Inhibidores peptídicos bicíclicos del receptor de interleuquina-23
UY39527A (es) Composiciones de los inhibidores de peptidos del receptor de interleucina-23
CO2024000999A2 (es) Inhibidores peptídicos lipídicos del receptor de interleucina-23
ECSP22063238A (es) Inhibidores de péptidos del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias
CR20210552A (es) Inhibidores del inflamasoma nlrp3
ECSP21004787A (es) Inhibidores de inflamasoma nlrp3
DOP2021000070A (es) Inhibidores de la proteína tirosina fosfatasa
SG10201810154WA (en) Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
UY38425A (es) Procesos novedosos para preparar n-((1,2,3,5,6,7-hexahidro-s-indacen-4-il)carbamoil)-1- isopropil-1h-pirazol-3-sulfonamida y sales de éste
AR119389A1 (es) Inhibidores de péptidos del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias
MX2022008740A (es) Peptidos inhibidores del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias.
BR112022000328A2 (pt) Inibidores peptídicos do receptor de interleucina-23 e seu uso para tratar doenças inflamatórias
CO2024001922A2 (es) Inhibidores de nlrp3
CL2022000998A1 (es) Inhibidores de las cinasas raf
CL2021000844A1 (es) Compuestos de indolinona para uso como inhibidores de map4k1
BR112017013728A2 (pt) dosagem de inibidor da btk a sítio específico
CO2020012169A2 (es) Compuestos de aminopirazina diol como inhibidores de pi3k-y
WO2023288028A3 (en) Peptide inhibitors of interleukin-23 receptor
CL2023002223A1 (es) Inhibidores de cdk2 y métodos de uso de los mismos
MX2022003671A (es) Inhibidores de proteina cinasa i de interaccion con receptores para el tratamiento de enfermedades.
CY1123644T1 (el) Τριπλος συνδυασμος καθαρων ανταγωνιστων του υποδοχεα 5-ητ6, αναστολεων της ακετυλοχολινεστερασης και του ανταγωνιστη του υποδοχεα nmda
CO2023003759A2 (es) Antagonista cristalino del receptor edg-2 y métodos de fabricación
CL2022002386A1 (es) Compuestos de amino pirimidina fusionados
CL2019003467A1 (es) Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias.
CO2024003953A2 (es) Derivados de benzodiazepina como moduladores alostéricos positivos del receptor de gaba a gamma1

Legal Events

Date Code Title Description
FB Suspension of granting procedure